Abstracts tagged "Biomarkers"

Abstract Number: 66 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Profiling of OA PBMCs Reveals Slowed Epigenetic Aging Among Rapid Radiographic Progressors: Data from the Osteoarthritis Initiative (OAI)
Alexander Rivas¹, Madison Andrews² and Matlock A. Jeffries³, ¹Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Department of Medicine, Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Extensive evidence has correlated epigenetic alterations in articular tissues with both the presence and progression of human osteoarthritis. A recent study demonstrated that accelerated…
Abstract Number: 649 • 2017 ACR/ARHP Annual Meeting
Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Roxana Coras^1,2, Arthur Kavanaugh¹, Doquyen H. Huynh¹, Aladdin Shadyab³, Sara Marsal⁴, Oswald Quehenberger⁵ and Monica Guma¹, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Barcelona, Spain, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain, ⁵Pharmacology, Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. There…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 1389 • 2017 ACR/ARHP Annual Meeting
Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Gunter Assmann¹, Silke Zinke², Moritz Gerling³, Natalie Fadle³, Klaus Dieter Preuss³, Michael Pfreundschuh³ and Lorenz Thurner³, ¹Medicine I, University Medical School of Saarland, 66424, Germany, ²Rheumapraxis, Rheumatology Center Berlin - Lichtenberg, Berlin, Germany, ³Medicine I, Jose Carreras Center, University of Saarland, Homburg, Germany
Background/Purpose: Until recently, most research on progranulin (PGRN) had been focused on its role in neurogenerative diseases as frontotemporal dementia. After the detection of elevated…
Abstract Number: 1977 • 2017 ACR/ARHP Annual Meeting
Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients
Victoria Furer¹, Eyal Hazan², Adi Mor³, Michal Segal³, Avi Katav³, Valerie Aloush⁴, Ori Elkayam⁴, Jacob George^3,5 and Jacob N. Ablin^6,7, ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ²Internal Medicine D, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³ChemomAb Ltd. Israel, Tel Aviv, Israel, ⁴Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Heart Institute, Kaplan Medical Center, Rehovot, Israel, ⁶Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Fibromyalgia is a widespread chronic pain syndrome (FMS) the pathogenesis of which remains incompletely understood. FMS patients demonstrate an altered profile of chemokines relative…
Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting
Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score
Md Yuzaiful Md Yusof^1,2, Yasser M El-Sherbiny^1,3, Antonios Psarras¹, Elizabeth M.A. Hensor^1,4, Adewonuola Alase¹, Alaa Mohamed¹, Miriam Wittmann^1,4, Paul Emery^1,4 and Edward M Vital^1,4, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁴ and Anca Askanase⁸, ¹Cohen Children's Medical Center of New York, Lake Success, NY, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Columbia University Medical Center, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Pediatrics, Columbia University Medical Center, New York, NY, ⁸Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
Dirk Holzinger¹, Carolin Pretzer², Maria Miranda-Garcia^2,3, Hans Huppertz⁴, Gerd Horneff⁵, Johannes Peter Haas⁶, Gerd Ganser⁷, Jasmin B. Kuemmerle-Deschner⁸, Michael Frosch⁹, Johannes Roth¹⁰ and Dirk Foell², ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ³Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institute, Langen, Germany, ⁴Prof Hess Children’s Hospital Bremen, Bremen, Germany, ⁵Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Pediatric Pain Centre,, Children's and Adolescents' Hospital Datteln, Datteln, Germany, ¹⁰Institute of Immunology, University of Muenster, Muenster, Germany
Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Elham Rezaei¹, Daniel Hogan², Brett Trost², Anthony Kusalik², Susanne Benseler³, Gilles Boire⁴, David A. Cabral⁵, Bonnie Cameron⁶, Sarah Campillo⁷, Gaëlle Chédeville⁸, Paul Dancey⁹, Ciarán M. Duffy¹⁰, Karen N Watanabe Duffy¹¹, Janet Ellsworth¹², Simon Eng¹³, Brian M. Feldman¹⁴, John Gordon², Jaime Guzman¹⁵, Kristin Houghton¹⁶, Adam Huber¹⁷, Quaid Morris¹³, Bianca Lang¹⁸, Deborah M. Levy¹⁹, Loren Matheson²⁰, Kiem Oen²¹, Ross Petty²², Suzanne Ramsey²³, Johannes Roth²⁴, Dax Rumsey²⁵, Claire Saint-Cyr²⁶, Rayfel Schneider²⁷, Rosie Scuccimarri²⁸, Earl Silverman¹⁹, Lynn R. Spiegel²⁹, Elizabeth Stringer¹⁸, Shirley M.L. Tse³⁰, Lori Tucker³¹, Rae S.M. Yeung³² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Montreal Children's Hospital, Montreal, QC, Canada, ⁸Rheumatology, McGill University, Montreal, QC, Canada, ⁹Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹²University of Alberta, Edmonton, AB, Canada, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, ¹⁷IWK Health Centre, Halifax, NS, Canada, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University of Saskatchewan, Ottawa, ON, Canada, ²¹University of Manitoba, Winnipeg, MB, Canada, ²²Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²³Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁴Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, ²⁵Stollery Children's Hospital, Edmonton, AB, Canada, ²⁶Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, ²⁷Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, ²⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ³⁰Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³¹Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ³²Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…
Abstract Number: 57 • 2017 Pediatric Rheumatology Symposium
Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis
Nikolay Tzaribachev¹, Romiesa Hagoug², Polymnia Louka³, Joyee Islam³, Mark Hinton³, Olga Kubassova⁴ and Mikael Boesen⁵, ¹PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ²Imaging, Image Analysis Group, London, United Kingdom, ³Image Analysis Group, London, United Kingdom, ⁴Image Analysis Group, Image Analysis Group, London, England, ⁵Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiskberg, Denmark
Background/Purpose: In chronic inflammatory conditions, the need for a more objective measurement of disease activity has been identified, where dynamic contrast enhanced (DCE) MRI as…
Abstract Number: 32 • 2017 Pediatric Rheumatology Symposium
High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
Hon Yan Ng¹, Stefan Slomp², Tracy Wilson-Gerwing³, Joan Dietz⁴, Abid Lodhi⁵, Tanya Holt⁶ and Alan Rosenberg³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Pediatrics, Emergency Medicine, University of Alberta, Edmonton, AB, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Regina Qu'appelle Health Region, Regina, SK, Canada, ⁶University of Saskatchewan, Sasktoon, SK, Canada
Background/Purpose: High Mobility Group Box 1 Protein (HMGB1) is a nuclear protein that stabilizes DNA and modulates gene expression. In sepsis and in certain other…
Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Nienke M. ter Haar¹, Rianne C. Scholman¹, Wilco de Jager², Nadia Ryter³, Ariane de Ganck⁴, Dirk Foell⁵, Sytze de Roock⁶ and Bas Vastert⁷, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³BÜHLMANN Laboratories AG, Basel, Switzerland, ⁴Biogazelle NV, Zwijnaarde, Belgium, ⁵Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…
Abstract Number: 143 • 2017 Pediatric Rheumatology Symposium
Influence of Age and Sex on Collagen-Induced Arthritis
Tracy Wilson-Gerwing¹, Arash Panahifar², David M.L. Cooper² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: Age and sex differences are found in certain subsets of juvenile idiopathic arthritis (JIA). Collagen Induced Arthritis (CIA) in rodents has utility in assessing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].